Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy

Highlight ► Identifying inflammatory markers (here, sTNF-R1 and IL-6) of chemoradiation-induced fatigue is a step toward confirming these biomarkers as a target for mechanism-based symptom management.

Saved in:
Bibliographic Details
Published in:Brain, behavior, and immunity behavior, and immunity, 2012-07, Vol.26 (5), p.699-705
Main Authors: Wang, Xin Shelley, Williams, Loretta A, Krishnan, Sunil, Liao, Zhongxing, Liu, Ping, Mao, Li, Shi, Qiuling, Mobley, Gary M, Woodruff, Jeanie F, Cleeland, Charles S
Format: Article
Language:English
Subjects:
Aged
Allergy and Immunology
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Body Mass Index
Cancer
Chemoradiation
Colorectal cancer
Colorectal Neoplasms - complications
Combined Modality Therapy - adverse effects
Cytokines
Cytokines - blood
Data Interpretation, Statistical
Esophageal cancer
Esophageal Neoplasms - complications
Fatigue
Fatigue - blood
Fatigue - etiology
Fatigue - psychology
Feeding and Eating Disorders - etiology
Female
Gastrointestinal Neoplasms - blood
Gastrointestinal Neoplasms - psychology
Gastrointestinal Neoplasms - therapy
Humans
Inflammation
Inflammation Mediators - blood
Interleukin-6 - blood
Longitudinal Studies
Male
MDASI
Middle Aged
Psychiatry
Radiotherapy - adverse effects
Receptors, Tumor Necrosis Factor, Type I - blood
Regression Analysis
Sickness behavior
Sleep Wake Disorders - etiology
Socioeconomic Factors
Stress, Psychological - etiology
Symptoms
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlight ► Identifying inflammatory markers (here, sTNF-R1 and IL-6) of chemoradiation-induced fatigue is a step toward confirming these biomarkers as a target for mechanism-based symptom management.
ISSN:0889-1591
1090-2139
DOI:10.1016/j.bbi.2011.12.007